Details

Autor(en) / Beteiligte

• Holder-Murray, Jennifer
• Esper, Stephen A
• Althans, Alison R
• Knight, Joshua
• Subramaniam, Kathirvel
• Derenzo, Joseph
• Ball, Ryan
• Beaman, Shawn
• Luke, Charles
• La Colla, Luca
• Schott, Nicholas
• Williams, Brian
• Lorenzi, Elizabeth
• Berry, Lindsay R
• Viele, Kert
• Berry, Scott
• Masters, Miranda
• Meister, Katie A
• Wilkinson, Todd
• Garrard, William
• Marroquin, Oscar C
• Mahajan, Aman

Titel

REMAP Periop: a randomised, embedded, multifactorial adaptive platform trial protocol for perioperative medicine to determine the optimal enhanced recovery pathway components in complex abdominal surgery patients within a US healthcare system

Ist Teil von

• BMJ open, 2023-12, Vol.13 (12), p.e078711-e078711

Ort / Verlag

England: British Medical Journal Publishing Group

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• IntroductionImplementation of enhanced recovery pathways (ERPs) has resulted in improved patient-centred outcomes and decreased costs. However, there is a lack of high-level evidence for many ERP elements. We have designed a randomised, embedded, multifactorial, adaptive platform perioperative medicine (REMAP Periop) trial to evaluate the effectiveness of several perioperative therapies for patients undergoing complex abdominal surgery as part of an ERP. This trial will begin with two domains: postoperative nausea/vomiting (PONV) prophylaxis and regional/neuraxial analgesia. Patients enrolled in the trial will be randomised to arms within both domains, with the possibility of adding additional domains in the future.Methods and analysisIn the PONV domain, patients are randomised to optimal versus supraoptimal prophylactic regimens. In the regional/neuraxial domain, patients are randomised to one of five different single-injection techniques/combination of techniques. The primary study endpoint is hospital-free days at 30 days, with additional domain-specific secondary endpoints of PONV incidence and postoperative opioid consumption. The efficacy of an intervention arm within a given domain will be evaluated at regular interim analyses using Bayesian statistical analysis. At the beginning of the trial, participants will have an equal probability of being allocated to any given intervention within a domain (ie, simple 1:1 randomisation), with response adaptive randomisation guiding changes to allocation ratios after interim analyses when applicable based on prespecified statistical triggers. Triggers met at interim analysis may also result in intervention dropping.Ethics and disseminationThe core protocol and domain-specific appendices were approved by the University of Pittsburgh Institutional Review Board. A waiver of informed consent was obtained for this trial. Trial results will be announced to the public and healthcare providers once prespecified statistical triggers of interest are reached as described in the core protocol, and the most favourable interventions will then be implemented as a standardised institutional protocol.Trial registration numberNCT04606264.